South Africa and Zambia are grappling with a significant challenge in rolling out lenacapavir, a new six-monthly HIV prevention injection. Despite high demand and promising early results, limited supplies mean clinics often run out of stock, creating a complex balancing act between generating awareness and ensuring equitable access. Read the full article